Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.

[1]  L. Collette,et al.  Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. , 2020, The Lancet. Oncology.

[2]  C. Dooms,et al.  Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  E. Goetghebeur,et al.  Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. , 2019, European urology.

[4]  V. Durieux,et al.  Defining synchronous oligometastatic non-small cell lung cancer: a systematic review. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  M. Guckenberger,et al.  Evolution of treatment strategies for oligometastatic NSCLC patients - A systematic review of the literature. , 2019, Cancer treatment reviews.

[6]  L. Uhlmann,et al.  Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT. , 2019, Clinical lung cancer.

[7]  Junhong Zhang,et al.  Stereotactic body radiotherapy improves the survival of patients with oligometastatic non‐small cell lung cancer , 2019, Cancer medicine.

[8]  A. Louie,et al.  A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead? , 2019, Front. Oncol..

[9]  R. Orecchia,et al.  Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions , 2019, Clinical & Experimental Metastasis.

[10]  Michael Lock,et al.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial , 2019, The Lancet.

[11]  J. Lee,et al.  Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Scorsetti,et al.  Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy. , 2019, International journal of radiation oncology, biology, physics.

[13]  B. Engels,et al.  The METABANK score: A clinical tool to predict survival after stereotactic radiotherapy for oligometastatic disease. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  M. Scorsetti,et al.  Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  Deepinder P. Singh,et al.  Hypofractionated Stereotactic Radiotherapy for Non-breast or Prostate Cancer Oligometastases: A Tail of Survival Beyond 10 Years , 2019, Front. Oncol..

[16]  S. Banerji,et al.  Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer. , 2019, Current oncology.

[17]  L. Collette,et al.  Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective. , 2019, The Lancet. Oncology.

[18]  V. Valentini,et al.  Dose escalation in extracranial stereotactic ablative radiotherapy (DESTROY-1): A multiarm Phase I trial. , 2019, The British journal of radiology.

[19]  P. Hu,et al.  Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations , 2019, Clinical lung cancer.

[20]  M. Scorsetti,et al.  Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma , 2019, The Journal of urology.

[21]  M. Hoogeman,et al.  Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy , 2018, Acta oncologica.

[22]  A. Costello,et al.  Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial , 2019, International journal of cancer.

[23]  Hong Wang,et al.  Initial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer. , 2019, International journal of radiation oncology, biology, physics.

[24]  J. Vandesompele,et al.  Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time , 2018, World Journal of Urology.

[25]  T. Eade,et al.  Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography. , 2018, European urology oncology.

[26]  Hollins P. Clark,et al.  Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer. , 2018, International journal of radiation oncology, biology, physics.

[27]  Hans T. Chung,et al.  Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy? , 2018, Lung cancer.

[28]  B. Rini,et al.  Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma , 2018, Clinical genitourinary cancer.

[29]  R. Miralbell,et al.  Oligorecurrent Nodal Prostate Cancer: Long-term Results of an Elective Nodal Irradiation Approach , 2018, American journal of clinical oncology.

[30]  A. Bertaut,et al.  Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  F. Alongi,et al.  Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study , 2018, Medical Oncology.

[32]  M. Scorsetti,et al.  The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer , 2018, Cancer medicine.

[33]  J. Aerts,et al.  Locoregional control and survival after lymph node SBRT in oligometastatic disease , 2018, Clinical & Experimental Metastasis.

[34]  R. Orecchia,et al.  Stereotactic Body Radiotherapy For Oligometastatic Ovarian Cancer: A Step Towards A Drug Holiday , 2018 .

[35]  G. Calais,et al.  Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group. , 2018, European journal of cancer.

[36]  L. Solbiati,et al.  Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation , 2018, Journal of Cancer Research and Clinical Oncology.

[37]  E. Cortesi,et al.  30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease. , 2018, Lung cancer.

[38]  N. Kopek,et al.  Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  C. Belka,et al.  Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease , 2018, Radiation Oncology.

[40]  Jorge Andrade,et al.  Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis , 2018, Nature Communications.

[41]  Hans T. Chung,et al.  Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[42]  M. Eble,et al.  Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[43]  R. Semrau,et al.  The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases , 2018, BMC Cancer.

[44]  B. V. Van Beers,et al.  Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group. , 2018, European journal of cancer.

[45]  D. Heron,et al.  Stereotactic Body Radiation Therapy for Pulmonary Oligometastases Arising from Non-lung Primaries in Patients Without Extrapulmonary Disease , 2018, Cureus.

[46]  E. Goetghebeur,et al.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  M. Hoogeman,et al.  Acute toxicity of the bowel after stereotactic robotic radiotherapy for abdominopelvic oligometastases , 2017, Acta oncologica.

[48]  R. Santoni,et al.  Oligometastatic cancer in elderly patients: the “blitzkrieg” radiotherapy approach , 2018, Aging Clinical and Experimental Research.

[49]  Timothy K. Nguyen,et al.  Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus Study. , 2018, Practical radiation oncology.

[50]  P. Iyengar,et al.  Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial , 2018, JAMA oncology.

[51]  F. Alongi,et al.  Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[52]  H. Klomp,et al.  Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases. , 2017, Lung cancer.

[53]  T. Treasure,et al.  Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial , 2017 .

[54]  P. Bondiau,et al.  Radiosensitivity of Colon and Rectal Lung Oligometastasis Treated With Stereotactic Ablative Radiotherapy , 2017, Clinical colorectal cancer.

[55]  Y. Lievens.  Access to innovative radiotherapy: how to make it happen from an economic perspective? , 2017, Acta oncologica.

[56]  R. Santoni,et al.  Oligometastatic cancer: stereotactic ablative radiotherapy for patients affected by isolated body metastasis , 2017, Acta oncologica.

[57]  D. Palma,et al.  Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases: An International Survey of >1000 Radiation Oncologists , 2017, American journal of clinical oncology.

[58]  T. Eade,et al.  Stereotactic Ablative Body Radiotherapy for the Treatment of Spinal Oligometastases. , 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

[59]  I. Poon,et al.  Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Histology, Dose, and Indication Matter. , 2017, International journal of radiation oncology, biology, physics.

[60]  H. Onishi,et al.  Dose Escalation Improves Outcome in Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer. , 2017, Anticancer research.

[61]  R. Semrau,et al.  Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[62]  F. Lohr,et al.  Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study , 2017, British Journal of Cancer.

[63]  A. Rimner,et al.  Palliative efficacy and local control of conventional radiotherapy for lung metastases. , 2017, Annals of palliative medicine.

[64]  J. Ledermann,et al.  Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial , 2017, Journal of the National Cancer Institute.

[65]  M. Scorsetti,et al.  Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours , 2017, Journal of Cancer Research and Clinical Oncology.

[66]  C. Sternberg,et al.  Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis , 2017, Oncotarget.

[67]  D. Heron,et al.  Patients with colorectal lung oligometastases (L-OMD) treated by dose adapted SABR at diagnosis of oligometastatic disease have better outcomes than patients previously treated for their metastatic disease. , 2017, Journal of radiosurgery and SBRT.

[68]  J. Lee,et al.  Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study , 2016, The Lancet. Oncology.

[69]  Henry Knipe,et al.  Oligometastases , 2016, Radiopaedia.org.

[70]  R. Weichselbaum,et al.  Clinical and molecular markers of long‐term survival after oligometastasis‐directed stereotactic body radiotherapy (SBRT) , 2016, Cancer.

[71]  M. Scorsetti,et al.  Role of Stereotactic Body Radiation Therapy with Volumetric-Modulated Arcs and High-Intensity Photon Beams for the Treatment of Abdomino-Pelvic Lymph-Node Metastases , 2016, Cancer investigation.

[72]  S. Kanazawa,et al.  Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases† , 2016, Japanese journal of clinical oncology.

[73]  L. Uhlmann,et al.  Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy". , 2016, Lung cancer.

[74]  C. Rübe,et al.  Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer , 2016, BMC Cancer.

[75]  Sean S. Park,et al.  Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer , 2016 .

[76]  H. Cárdenes,et al.  Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. , 2016, Practical radiation oncology.

[77]  Ping Wang,et al.  Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes , 2016, Oncotarget.

[78]  Y. Takai,et al.  Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study , 2015, Journal of radiation research.

[79]  M. Scorsetti,et al.  Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

[80]  N. V. As,et al.  Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis. , 2016, European urology.

[81]  L. Miszczyk,et al.  CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases. , 2016, Neoplasma.

[82]  W. Jang,et al.  Stereotactic Body Radiotherapy for Recurrent or Oligometastatic Uterine Cervix Cancer: A Cooperative Study of the Korean Radiation Oncology Group (KROG 14-11). , 2015, Anticancer research.

[83]  B. Loo,et al.  Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy. , 2015, International journal of radiation oncology, biology, physics.

[84]  T. Eade,et al.  Comparison of Single-fraction and Multi-fraction Stereotactic Radiotherapy for Patients with 18F-fluorodeoxyglucose Positron Emission Tomography-staged Pulmonary Oligometastases. , 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

[85]  W. Jang,et al.  Stereotactic Body Radiotherapy for Oligometastases Confined to the Para-Aortic Region: Clinical Outcomes and the Significance of Radiotherapy Field and Dose , 2015, Cancer investigation.

[86]  K. Pienta,et al.  The biology and treatment of oligometastatic cancer , 2015, Oncotarget.

[87]  P. Hoskin,et al.  Stereotactic body radiotherapy (SBRT) in the management of extracranial oligometastatic (OM) disease. , 2015, The British journal of radiology.

[88]  M. Høyer,et al.  Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[89]  I. Poon,et al.  Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[90]  David A. Palma,et al.  The oligometastatic state—separating truth from wishful thinking , 2014, Nature Reviews Clinical Oncology.

[91]  K. Decaestecker,et al.  Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence , 2014, Radiation oncology.

[92]  G. Baroni,et al.  Linac-based Stereotactic Body Radiotherapy for Oligometastatic Patients With Single Abdominal Lymph Node Recurrent Cancer , 2014, American journal of clinical oncology.

[93]  M. Scorsetti,et al.  Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments , 2014, Radiation oncology.

[94]  Sean S. Park,et al.  Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases. , 2014, Practical radiation oncology.

[95]  M De Ridder,et al.  Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[96]  E. Cortesi,et al.  Clinical outcomes of single dose stereotactic radiotherapy for lung metastases. , 2013, Clinical lung cancer.

[97]  Charles M. Miller,et al.  Multicentre results of stereotactic body radiotherapy for secondary liver tumours. , 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[98]  O. Ratib,et al.  Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases , 2013, Acta oncologica.

[99]  Merina Ahmed,et al.  Stereotactic body radiotherapy for oligometastases. , 2013, The Lancet. Oncology.

[100]  Oleksiy Karpenko,et al.  Oligo- and Polymetastatic Progression in Lung Metastasis(es) Patients Is Associated with Specific MicroRNAs , 2012, PloS one.

[101]  P. Okunieff,et al.  Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. , 2012, International journal of radiation oncology, biology, physics.

[102]  D. Lim,et al.  Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung , 2012, Acta oncologica.

[103]  R. Weichselbaum,et al.  MicroRNA Expression Characterizes Oligometastasis(es) , 2011, PloS one.

[104]  F. Petrella,et al.  A 10-Year Single-Center Experience on 708 Lung Metastasectomies: The Evidence of the “International Registry of Lung Metastases” , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[105]  K. Rosenzweig,et al.  Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. , 2011, International journal of radiation oncology, biology, physics.

[106]  Dong Han Lee,et al.  Oligometastases confined one organ from colorectal cancer treated by SBRT , 2010, Clinical & Experimental Metastasis.

[107]  Y. Niibe,et al.  Oligometastases and Oligo-recurrence: The New Era of Cancer Therapy , 2010, Japanese journal of clinical oncology.

[108]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[109]  M. Gonen,et al.  Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. , 2007, Journal of the American College of Surgeons.

[110]  J. Petersen,et al.  Phase II study on stereotactic body radiotherapy of colorectal metastases , 2006, Acta oncologica.

[111]  H. von der Maase,et al.  Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[112]  L H Blumgart,et al.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. , 1999, Annals of surgery.

[113]  E. Elias,et al.  Metastatic Carcinomas from Occult Primary Tumors: A Study of 254 Patients , 1977, Annals of surgery.